Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00897806 · ClinicalTrials.gov registry record
Identifying Genetic Markers That Predict Response to Paclitaxel in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer
A clinical trial, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- 7
- Enrollment target
NCT00897806: Clinical Trial study, sponsored by M.D. Anderson Cancer Center.
NCT00897806 is a clinical trial that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00897806 was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- 7 participants
- Enrollment target
Study Summary
RATIONALE: DNA analysis of tumor tissue from patients with cancer may help doctors predict how patients respond to treatment and plan the best treatment. PURPOSE: This laboratory study is identifying genetic markers that predict response to paclitaxel in patients with newly diagnosed stage III or stage IV ovarian epithelial cancer or primary peritoneal cancer.
Interventions
- OTHER Laboratory biomarker analysis
- GENETIC Microarray analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2002-02 |
| Est. Completion | 2009-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00897806
The ClinicalTrials.gov registry entry for NCT00897806 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Laboratory biomarker analysis is the first listed.
NCT00897806 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00897806 about?
NCT00897806 is a clinical study titled "Identifying Genetic Markers That Predict Response to Paclitaxel in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer". RATIONALE: DNA analysis of tumor tissue from patients with cancer may help doctors predict how patients respond to treatment and plan the best treatment. PURPOSE: This laboratory study is identifying genetic markers that predict response to paclitaxel in patients with newly diagnosed stage III or s...
What is the current status of trial NCT00897806?
This trial is currently terminated. The enrollment target is 7 participants. The study started on 2002-02. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00897806?
The interventions under investigation include: Laboratory biomarker analysis (OTHER), Microarray analysis (GENETIC).
Who is sponsoring clinical trial NCT00897806?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.